Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 06-07-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | Unum Therapeutics Inc Placement of Preferred Stock | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Unum Therapeutics Inc., a biopharmaceutical company focused on developing therapies for solid tumors, announced it had completed the acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. Concurrent with the acquisition of Kiq, Unum entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC, with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor's LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed institutional investors.
Latham and Watkins LLP represented Jefferies LLC, the lead placement agent for the private placement.
|
||
| Financial Center: | New York | Value: | 0.00-0.00 |
| Advised Party: | Issuer | Law Firm | Latham & Watkins |
| Issuer Jurisdiction - | United States | Listing Jurisdiction - | United States |
| Classification: |
Secondary Offerings and Placings NYSE: |
Lawyer | Nathan Ajiashvili |
